Does UROSHIELD® Influence Bacterial Growth On Endotracheal Tubes (lungshield)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02074306|
Recruitment Status : Recruiting
First Posted : February 28, 2014
Last Update Posted : August 7, 2018
|Condition or disease||Intervention/treatment||Phase|
|Mechanical Ventilation Complication||Device: UROSHIELD® Device: SHAM UROSHIELD®||Not Applicable|
Ventilator Associated Pneumonia (VAP) is a common complication in patients treated by mechanical ventilation, supposedly related to development of bacterial colonization on the endotracheal tubes. Therefore many devices were designed to address this issue.
NanovibronixTM Company developed "UROSHIELD®" a device which generates low energy ultrasound wave in the nanometer range, and delivers these waves by an actuator which is connected externally to a urinary catheter. It was shown that using UROSHIELD®, there was reduction in development of bacterial colonies, and lower rate of resistance of bacteria to antibiotics.
Aim of the study:
To examine the effect of UROSHIELD® on development of bacterial colonies on endotracheal tubes, in patient receiving mechanical ventilation, and to determine whether this device lowers the rate of bacterial resistance to antibiotics.
Consecutive patients, with newly begun mechanical ventilation, will be connected to UROSHIELD® within 48 hours. Endotracheal secretions will be collected for culture and antibiotic sensitivity every 3 days for 15 consecutive days or until disconnection from the mechanical ventilation. Half of the devices will be active for the study group; the other half will be sham for the control. The devices will externally look identical and will have a serial number which will remain secret.
Primary end point: The time to convert the sputum culture from negative to positive.
Secondary end points: The number of positive cultures with virulent bacteria and the rate of development of resistance to antibiotics will also be compared.
By statistical analysis the investigators conclude that enrollment of 33 patients into each group will allow significant results to be detected.
Should the study group show longer time to convert to positive bacterial culture and/or lower antibiotic resistance, the use of UROSHIELD®, should be examined in a larger study, with reduction of VAP as a primary end point.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||66 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Does UROSHIELD® Influence Bacterial Growth On Endotracheal Tubes|
|Study Start Date :||April 2016|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
Randomly selected patients,(ratio 1:1) with newly begun mechanical ventilation, will be connected to a low energy acustic wave generator UROSHIELD® within 48 hours. Endotracheal secretions will be collected for culture and antibiotic sensitivity every 3 days for 15 consecutive days or until disconnection from the mechanical ventilation.
An active UROSHIELD® device (low energy acustic wave generator) will be connected to an intratracheal tube externally. The device will transform low energy ultrasound waves on to the tube. These waves will by assumption lower the formation of bacterial growth and resistance to antibiotics.
Other Name: LUNGSHIELD®
Sham Comparator: SHAM UROSHIELD®
same as abouve but with Sham device.
Device: SHAM UROSHIELD®
SHAM UROSHIELD® will be connected to endotracheal tubes unable to transform any waves.
Other Name: SHAM LUNGSHIELD®
- Number of days elapse until development of positive sputum culture [ Time Frame: 15-20 days ]Sputum for culture will be obtained every 3 days. Number of days till sputum culture will convert from negative to positive one will be calculated and compared for the study and control groups.
- Type of bacteria and antibiotic sensitivity [ Time Frame: 15-20 days ]
Types of bacteria and their sensitivities to antibiotics will be evaluated. Comparison will be done between rate of growth of serious pathogens (e.g., Methicillin resistant staphylococcus aureus (MRSA),Vancomycin-Resistant Enterococci (VRE)) in the study and control groups.
Rate of resistance development to antibiotics will also be compared.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02074306
|Contact: Reuven Friedmann, Dremail@example.com|
|Medical wing, Shaare Zedek Medical Center||Recruiting|
|Jerusalem, Israel, 9103102|
|Contact: Reuven Friedmann, Dr 972508685156 firstname.lastname@example.org|
|Principal Investigator: Reuven Friedmann, Dr|
|Study Director:||Reuven Friedmann, Dr||Shaare Zedek Medical Center|